Company Overview

PetVivo Holdings, Inc. is a U.S.-based biomedical and medical device company focused on the development, commercialization, and licensing of veterinary therapeutics for companion animals and horses. The company operates primarily within the veterinary health, regenerative medicine, and animal therapeutics industries, with a commercial emphasis on osteoarthritis and joint-related conditions in animals. Its principal revenue driver is the sale of its lead veterinary medical device product, SPRYNG with OsteoCushion Technology, an intra-articular injectable intended for the management of lameness and joint dysfunction in dogs and horses. The company also maintains a pipeline of biomaterials and veterinary therapeutic technologies aimed at addressing musculoskeletal disorders.

PetVivo was founded in 2009 and evolved from a research-oriented regenerative medicine company into a commercial-stage veterinary device business. The company’s strategy has centered on adapting biomaterials and tissue engineering technologies originally developed for human medicine into veterinary applications. Public filings and investor disclosures indicate that PetVivo positions itself through a combination of proprietary biomaterial science, veterinary-focused commercialization, and a niche emphasis on non-surgical treatment alternatives for osteoarthritis in companion animals and equine markets.

Business Operations

PetVivo primarily generates revenue through product sales, distributor relationships, and veterinary clinic adoption of SPRYNG with OsteoCushion Technology. The company’s operations are focused largely in the United States, although it has pursued international distribution opportunities in select foreign markets. PetVivo operates as a single-reporting business centered on veterinary medical devices and biologic-related technologies. Its commercialization strategy includes direct sales representatives, independent distributors, veterinary conferences, educational outreach, and strategic partnerships with veterinary service providers.

The company controls proprietary biomaterial technologies associated with its injectable osteoarthritis treatments and maintains intellectual property related to cartilage support and cushioning applications. PetVivo has disclosed collaborations and distribution arrangements intended to expand veterinary clinic penetration and market awareness. Public filings also reference subsidiaries and affiliated operational entities used for intellectual property management and commercialization support, although the company remains relatively concentrated around its flagship product platform compared with larger diversified animal health companies.

Strategic Position & Investments

PetVivo’s strategic direction has focused on expanding market adoption of SPRYNG with OsteoCushion Technology within the companion animal and equine sectors while advancing additional therapeutic candidates from its biomaterials platform. The company has invested in veterinary sales infrastructure, clinical education programs, and expanded manufacturing and distribution capabilities intended to support recurring utilization by veterinarians. Public disclosures also indicate ongoing efforts to increase reimbursement awareness and establish broader clinical validation through practitioner experience and case studies.

The company operates within the growing veterinary regenerative medicine and animal mobility treatment market, which has experienced increased demand due to rising pet ownership, longer companion animal lifespans, and greater spending on advanced veterinary care. PetVivo has also explored strategic collaborations and licensing opportunities related to regenerative therapeutics and biomaterials. While the company has discussed additional product development initiatives in investor communications and regulatory filings, available public information indicates that commercialization remains heavily dependent on the performance and adoption trajectory of its lead product platform.

Geographic Footprint

PetVivo is headquartered in Minnesota, United States, and its primary commercial operations are concentrated in the U.S. veterinary market. The company markets its products primarily to veterinary clinics, specialty veterinary practices, and equine practitioners across the United States. Public disclosures indicate that the company has sought to establish broader distribution relationships in select international markets, though its operational footprint remains substantially North America-focused.

The company’s customer base includes veterinarians serving companion animals and performance horses, with growing emphasis on canine osteoarthritis treatment applications. PetVivo’s international strategy has included evaluating distributor-led expansion opportunities in regions where veterinary regenerative medicine and advanced orthopedic treatments are gaining adoption. However, available public filings indicate that the majority of revenue and operational activity continues to originate from domestic markets.

Leadership & Governance

PetVivo’s leadership team has emphasized commercialization execution, veterinary market penetration, and continued development of biomaterial-based therapeutic technologies. The company’s governance structure follows standard public company practices, including oversight by a board of directors and executive leadership responsible for operational, financial, and commercialization activities. Corporate communications and SEC disclosures indicate that management’s strategic vision centers on establishing PetVivo as a differentiated veterinary therapeutics company focused on minimally invasive treatment solutions for joint disease and mobility disorders.

Key executives and leadership figures include:

• John Lai – Chief Executive Officer
• John Lai – President
• Bruce M. Paquin – Chief Financial Officer
• Gregg A. Rich – Executive Vice President of Commercial Operations
• Randy Hubbell, DVM, MBA – Chief Veterinary Medical Officer

Executive roles and leadership composition may change over time based on company filings and governance updates. Publicly available information regarding certain executive responsibilities and historical leadership transitions is limited in some cases, and data may vary across reporting periods.